Polygenic risk scores for schizophrenia and treatment resistance: New data, systematic review and meta-analysis

[1]  J. Costas,et al.  Association between psychiatric hospitalizations of patients with schizophrenia and polygenic risk scores based on genes with altered expression by antipsychotics , 2022, Acta psychiatrica Scandinavica.

[2]  Michael F. Green,et al.  Mapping genomic loci implicates genes and synaptic biology in schizophrenia , 2022, Nature.

[3]  R. Kahn,et al.  Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders , 2022, Translational Psychiatry.

[4]  A. Gadelha,et al.  Systems-Level Analysis of Genetic Variants Reveals Functional and Spatiotemporal Context in Treatment-resistant Schizophrenia , 2022, Molecular Neurobiology.

[5]  D. Rujescu,et al.  Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia , 2022, JAMA psychiatry.

[6]  J. MacCabe,et al.  Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis , 2021, The British Journal of Psychiatry.

[7]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[8]  G. Breen,et al.  Evaluation of polygenic prediction methodology within a reference-standardized framework , 2020, bioRxiv.

[9]  P. Sullivan,et al.  Chronicity and Sex Affect Genetic Risk Prediction in Schizophrenia , 2020, Frontiers in Psychiatry.

[10]  S. Djurovic,et al.  Indicated association between polygenic risk score and treatment-resistance in a naturalistic sample of patients with schizophrenia spectrum disorders , 2020, Schizophrenia Research.

[11]  P. Sullivan,et al.  Increased schizophrenia family history burden and reduced premorbid IQ in treatment-resistant schizophrenia: a Swedish National Register and Genomic Study , 2019, Molecular Psychiatry.

[12]  A. Sawa,et al.  Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives , 2019, Neurobiology of Disease.

[13]  R. Murray,et al.  Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies , 2019, Psychological Medicine.

[14]  G. Kirov,et al.  Clinical indicators of treatment-resistant psychosis , 2019, The British Journal of Psychiatry.

[15]  C. Pisanu,et al.  Treatment-Resistant Schizophrenia: Insights From Genetic Studies and Machine Learning Approaches , 2019, Front. Pharmacol..

[16]  A. Malhotra,et al.  Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis. , 2019, The American journal of psychiatry.

[17]  T. Werge,et al.  Schizophrenia polygenic risk scores, urbanicity and treatment-resistant schizophrenia , 2019, Schizophrenia Research.

[18]  G. Remington,et al.  The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review , 2018, Psychiatry Research.

[19]  Farooq Naeem,et al.  Barriers to using clozapine in treatment-resistant schizophrenia: systematic review , 2018, BJPsych Bulletin.

[20]  Jakob Grove,et al.  Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection , 2018, Nature Genetics.

[21]  C. Gasse,et al.  Polygenic Risk Score for Schizophrenia and Treatment-Resistant Schizophrenia , 2017, Schizophrenia bulletin.

[22]  A. Sawa,et al.  Clozapine as a Model for Antipsychotic Development , 2017, Neurotherapeutics.

[23]  D. Siskind,et al.  The impact of clozapine on hospital use: a systematic review and meta‐analysis , 2017, Acta psychiatrica Scandinavica.

[24]  Robert M. Maier,et al.  High loading of polygenic risk in cases with chronic schizophrenia , 2016, Molecular Psychiatry.

[25]  Michael J. Keiser,et al.  Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach. , 2016, The lancet. Psychiatry.

[26]  Dennis R. Grayson,et al.  Altering the course of schizophrenia: progress and perspectives , 2016, Nature Reviews Drug Discovery.

[27]  M. Owen,et al.  Schizophrenia , 2016, The Lancet.

[28]  Andrew K. Martin,et al.  Increased rare duplication burden genomewide in patients with treatment-resistant schizophrenia , 2015, Psychological Medicine.

[29]  D. Rujescu,et al.  Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients , 2015, Molecular Psychiatry.

[30]  V. Anderson,et al.  Extensive Gray Matter Volume Reduction in Treatment-Resistant Schizophrenia , 2015, The international journal of neuropsychopharmacology.

[31]  Carson C Chow,et al.  Second-generation PLINK: rising to the challenge of larger and richer datasets , 2014, GigaScience.

[32]  C. Spencer,et al.  Biological Insights From 108 Schizophrenia-Associated Genetic Loci , 2014, Nature.

[33]  D. Rujescu,et al.  Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients , 2014, Molecular Psychiatry.

[34]  R. Murray,et al.  Antipsychotic Treatment Resistance in Schizophrenia Associated with Elevated Glutamate Levels but Normal Dopamine Function , 2014, Biological Psychiatry.

[35]  F. Iasevoli,et al.  Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: Correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses , 2013, Psychiatry Research.

[36]  P. McGorry,et al.  Risk factors for relapse following treatment for first episode psychosis: A systematic review and meta-analysis of longitudinal studies , 2012, Schizophrenia Research.

[37]  Anders D. Børglum,et al.  Genome-wide association study identifies five new schizophrenia loci , 2011, Nature Genetics.

[38]  J. Ioannidis,et al.  Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials , 2011, BMJ : British Medical Journal.

[39]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration , 2009, BMJ : British Medical Journal.

[40]  S. Kumra,et al.  Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study. , 2008, Journal of child and adolescent psychopharmacology.

[41]  H. Hippius.  A historical perspective of clozapine. , 1999, The Journal of clinical psychiatry.

[42]  David Taylor,et al.  Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. , 2003, The Journal of clinical psychiatry.